Primary Sclerosing Cholangitis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Primary Sclerosing Cholangitis – Pipeline Review, H1 2020’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis

– The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects

– The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Allergan Plc

BiomX Inc

ChemomAb Ltd

Dr. Falk Pharma GmbH

Emergent Biotechnologies LLC

Engitix Ltd

Gilead Sciences Inc

Immunic Inc

Intercept Pharmaceuticals Inc

Mirum Pharmaceuticals Inc

Morphic Holding Inc

NGM Biopharmaceuticals Inc

Nyrada Inc

Orbsen Therapeutics Ltd

Pliant Therapeutics Inc

Qing Bile Therapeutics Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Sirnaomics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Sclerosing Cholangitis Overview

Primary Sclerosing Cholangitis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Sclerosing Cholangitis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Sclerosing Cholangitis Companies Involved in Therapeutics Development

Albireo Pharma Inc

Allergan Plc

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Gilead Sciences Inc

Immunic Inc

Intercept Pharmaceuticals Inc

Morphic Holding Inc

NGM Biopharmaceuticals Inc

Nyrada Inc

Pliant Therapeutics Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Sirnaomics Inc

Takeda Pharmaceutical Co Ltd

Primary Sclerosing Cholangitis Drug Profiles

berberine ursodeoxycholate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Liver Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bulevirtide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BX-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cilofexor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTD-1801 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-838 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

norursodeoxycholic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-205 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odevixibat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-1177 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-1561 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-1705 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-74809 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QBT-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QBT-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-435 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar lysine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha 5 and Beta 6 for Non-Alcoholic Steatohepatitis and Primary Sclerosing Cholangitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volixibat potassium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Sclerosing Cholangitis Dormant Projects

Primary Sclerosing Cholangitis Discontinued Products

Primary Sclerosing Cholangitis Product Development Milestones

Featured News & Press Releases

Aug 12, 2019: Immunic, announces first patient enrolled in investigator-sponsored proof-of-concept clinical trial of IMU-838 for the treatment of patients with primary sclerosing cholangitis

Jun 28, 2019: Pliant Therapeutics completes trial of PLN-74809 to treat in IPF

Jun 18, 2019: CymaBay Therapeutics announces IND to commence a clinical study of Seladelpar to treat primary sclerosing cholangitis

Apr 08, 2019: NGM Bio announces presentation of abstracts on NGM282 at The International Liver Congress 2019

Apr 08, 2019: Sirnaomics to present at World Orphan Drug Congress 2019

Apr 08, 2019: Clinical trial investigates Orbsen Therapeutics ORBCEL-C immunotherapy as treatment for two autoimmune liver diseases

Feb 15, 2019: CymaBay Therapeutics announces seladelpar granted breakthrough therapy designation by the FDA for the treatment of primary biliary cholangitis

Jan 03, 2019: Pliant Therapeutics initiates phase 1 clinical study of PLN-74809

Nov 20, 2018: Pliant Therapeutics receives FDA orphan drug designation for lead program PLN-74809 in primary sclerosing cholangitis

Nov 09, 2018: Pliant Therapeutics presents preclinical data on integrin inhibitors at The Liver Meeting 2018

Nov 09, 2018: Gilead announces positive phase 2 results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting 2018

Oct 11, 2018: Gilead to present data on Primary Sclerosing Cholangitis drug candidate GS-9674 at The Liver Meeting 2018

Oct 03, 2018: HighTide Therapeutics presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day

Sep 27, 2018: HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis

Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Albireo Pharma Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Allergan Plc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by BiomX Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by ChemomAb Ltd, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Dr. Falk Pharma GmbH, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Emergent Biotechnologies LLC, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Engitix Ltd, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Gilead Sciences Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Immunic Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Intercept Pharmaceuticals Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Mirum Pharmaceuticals Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Morphic Holding Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by NGM Biopharmaceuticals Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Nyrada Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Orbsen Therapeutics Ltd, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Pliant Therapeutics Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Qing Bile Therapeutics Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Seres Therapeutics Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Sirnaomics Inc, H1 2020

Primary Sclerosing Cholangitis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Primary Sclerosing Cholangitis – Dormant Projects, H1 2020

Primary Sclerosing Cholangitis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports